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Abstract The MAGhaler (Mundipharma GmbH) is amultidose drypowder inhaler (DPI) containinga novel formula-
tion of drug and lactose compacted by an isostatic pressing technique (GGUGmbH).On actuation, a precise dose is
metered from a compacted ring-shaped drug tablet. In this study, the lung deposition of salbutamol fromthis device has
been assessed.Ten healthy non-smoking subjects completed a two-way cross-over study, assessing the pulmonary de-
position of salbutamol (200 mg) fromthe MAGhaler at high (60 l/min) and low (30 l/min) peak inhaled flowrates (PIFRs),
representingmaximal and sub-maximal inspiratory efforts.The formulationwas radiolabelledwith 99mTc, and lung and
oropharyngealdepositionswerequantifiedbygamma scintigraphy.Themean (SD)%ofthedelivereddosedepositedinthe
lungswas 26.4 (4.3)% at 60 l/min and 21.1 (5.1)% at 30 l/min (Po0.05), corresponding tomeanlungdepositions of 52.8 and
42.2 mg salbutamol, respectively.The distribution of drug within different lung regions did not vary significantly with in-
haled flow rate.The data provided proof of concept for the novel inhaler device and the innovative drug formulation. In
comparison with previous deposition data obtained with other DPIs, the lung deposition was relatively high, relatively
reproducible (coefficient of variation16% at 60 l/min) and relatively insensitive to the change in peak inhaled flow rate.
r 2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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The pressurised metered dose inhaler (pMDI) has
been the most important inhaler device for the
delivery of asthma drugs over several decades, but fol-
lowing the ban placed upon the production of chloro-
£uorocarbon (CFC) propellants by the Montreal
Protocol (1), there has been much interest in the devel-
opment of alternative inhaler technologies.Dry powder
inhalers (DPIs) were ¢rst introduced almost 30 years ago
(2), but until relatively recently the available devices
were single-dose units, with the drug contained in gela-
tine capsules. Several multidose DPIs are now available,
with the drug either metered from a reservoir of free-
£owingpowder (3), or contained in individually ¢lledblis-
ters (4).
Micronised powders are highly sensitive to atmo-
spheric factors (for instance moisture, electrostaticReceived 8 April 2002, accepted in revised form 29 April 2002
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@pharmpro¢les.co.ukcharge and oxidation), which may reduce both ¢ne
particle dose and dosage accuracy (5). Several new ‘‘next
generation’’ DPIs have been designed to deliver a
more reliable and reproducible dose. The MAGhaler
(Mundipharma GmbH, Fig. 1) ‘‘Mechanical Aerosol Gen-
erator’’ device contains a novel powder formulation, in
which a blend of drug and lactose is compacted into a
ring-tablet using a specially developed radial isostatic
pressing technique (GGU GmbH) before being as-
sembled into the inhaler.The device includes a mechani-
cally wound drive unit intended for long-term use,
incorporating a grinding wheel with a face-cutter.When
the patient presses a button to actuate the device, an ac-
curately metered dose of drug is milled from the front
surface of the ring-tablet, and the patient’s inhalation is
thenused to deliver thepowder to therespiratory tract.
In this study, a formulation of salbutamol has been radi-
olabelledwith the radionuclide 99mTc, so that its deposi-
tion in the human respiratory tract could be assessed by
gamma scintigraphy (6).The e¡ects of inhaling at fast and
slow inhaled £ow rates, representing maximal and sub-
maximal inspiratory e¡orts respectively, were com-
pared.
FIG. 1. The MAGhalerdevice (Mundipharma GmbH), showingdevice andring-tablet (GGUGmbH).
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Study design
Ten healthy non-smoking volunteers (7 male, 3 female,
aged 25 ^ 56 years), all with forced expiratory volume
in 1s (FEV1)480% of the predicted value for their age,
sex and height (7) took part in the study. Each subject
gave written consent to the investigation, following an
explanation of the study both verbally and in writing.
The Quorn Research Review Committee (Leicester-
shire, U.K.) gave permission for the study to be per-
formed, and the administration of radioactivity to the
subjects was approved by the Department of Health,
U.K. The study was conducted in accordance with the
Declaration of Helsinki. The study was a randomised
two-way cross-over investigation with a minimum of
48h between each study leg.On each study day, subjects
inhaled, in rapid succession, two100mg doses of salbuta-
mol (total 200mg) using either maximal inspiratory ef-
fort (targeted peak inhaled £ow rate, PIFR, 60 l/min) or
a sub-maximal inspiratory e¡ort (targeted PIFR 30 l/
min).
Manufacture of radiolabelled formulations
A highly compacted ring-shaped tablet containing salbu-
tamol, lactose and 99m Tc was manufactured on each
studyday.Themethodused to radiolabel the formulation
was based partly upon that applied previously to other
drug/lactose blends (8). Approximately 10GBq 99m Tc
was dissolved in a non-aqueous solvent before being
added to micronised salbutamol (0.170 g). After evapora-
tion of the solvent, the radiolabelled salbutamol was
blended with lactose (2.132g) using a purpose-built
mini-mixing device (GGU GmbH). The powder blend
was then compressed isostatically (CIP 1000 isostaticpress, ABB Industries) at a pressure of152 MPa, to give a
ring-tablet of density1.32 g/cm3.Thering-tabletwas then
assembled into a MAGhaler device. Each dose contained
100mg salbutamol and approximately1.2mg lactose. Suf-
¢cient 99mTc was used to ensure that following a period
of radioactive decay between manufacture and dosing,
each dose contained a maximum 5MBq in the clinical
study.
Radiolabelling validation
In order to demonstrate the quality of the radiolabelling,
validation experiments were carried out in advance of
the studydays themselves (9,10), involving a series of radi-
olabelled andnon-radiolabelled salbutamol formulations.
The particle size distributions of drug before labelling
(n=4), drug after labelling (n=6) andradiolabel (n=6) were
obtained using a 5-stage high-precision multistage liquid
impinger (HPMLI, Copley Instruments, Nottingham,
U.K.) operating at 60 l/min.The stageswerewashedwith
methanol, and drug recovered from each stage was as-
sayed by ultraviolet spectroscopy. 99m Tc radiolabel re-
covered from each stage was quanti¢ed by gamma
counting. The ¢ne particle fractions (FPFs) of drug and
radiolabel (percentages of drug or radiolabel recovered
from stages 3^5 of the impinger) were calculated as per-
centages of delivered dose. The study inhalers used on
the study days were also assessed before the subjects
were dosed in order to ensure that the FPFs of the radi-
olabel were comparable to the range of values seen in
the pre-study validation experiments.
Measurement of delivered dose
The delivered dose of salbutamol from the MAGhaler
was measured at £ow rates of both 60 and 30 l/min. A
1028 RESPIRATORYMEDICINEseries of10 successive doseswere taken fromeach of two
non-radiolabelledMAGhalers, andwere extracted into a
unit dose sampling apparatus at the required £ow rate.
The amount of drug collected in the sampling apparatus
was quanti¢edby high-performance liquid chromatogra-
phy.
Administration of radiolabelled salbutamol
powder
The radiolabelled drug formulation was administered
with the inhaler device connected in serieswith a Vitalo-
graph pMDI-Compact Spirometer (Vitalograph Ltd.,
Maids Moreton,U.K.), so that the inhalation £ow and in-
halation volume could be determined. The spirometer
displayed inhaled £ow rate vs. time on a screen which
subjects could see as they inhaled, and they were in-
structed to keep the PIFR between a set of ‘‘tram lines’’
on the screen, setbetween 50 and 70 l/min for a targeted
value of 60 l/min, and between 20 and 40 l/min for a tar-
geted value of 30 l/min. Following each inhalation, sub-
jects were instructed to hold their breath for 10 s and
then exhale into a ¢lter.Once the subject had practiced
the inhalation manoeuvre with a blank device, and had
achieved the required inhalation technique reproducibly,
the blank device was replaced with a device containing
the radiolabelled formulation. In order to minimise the
duration of the dosing procedure, only the inhalation de-
tails from the second of the two doses on each study day
were recorded.
In vivomeasurements
Scintigraphic images of the chest (posterior and anterior,
duration 100 s), lateral oropharynx (duration 30 s), and
exhalation ¢lter were recorded immediately after inhala-
tion by gamma camera (General Electric Maxicamera,
Madison,WI,U.S.A.), connected to a Park Medical Micas
Vdata processing system (Farnborough,U.K.). A poster-
ior lung ventilation scanwasperformedon one studyday
using the radioactive inert gas 81mKr, and the lung out-
lines from the ventilation scan were used to de¢ne the
lung borders on the aerosol views.The lungs were subdi-
vided into three zones (central, intermediate andperiph-
eral zones) representing primarily large, medium and
small diameter airways, respectively (11). Regions of in-
terest were also drawn around the oropharynx, oeso-
phagus and stomach, and the geometric means of
anterior and posterior lung, oesophagus and stomach
countswere calculated.Countswere corrected for back-
ground radioactivity, radioactive decay, and for the at-
tenuation of gamma rays by overlying tissues (12). The
corrected counts from lungs, oropharynx (including oe-
sophagus and stomach) and exhaled air ¢lter were
summed, and percentage of the delivered dose locatedat each site was calculated by expressing the count re-
corded from each site as a percentage of the total count.
The mouthpiece of the inhaler device could not be re-
moved, so it was not possible to quantify retention of
the dose on the device itself. The lung deposition data
were expressed for each subject as mass of salbutamol
by multiplying the percentage lung deposition ¢gures by
themean delivered dose.
Spirometric tests of lung function [FEV1, forced vital
capacity (FVC) and peak exhaled £ow (PEF)] were mea-
sured before inhalation, and 30 minutes later (Microloop
Spirometer,MicroMedical, Rochester,U.K.).
Statistical analysis
TheWilcoxonmatched-pairs signed ranks test was used
to determine whether di¡erences between the deposi-
tion patterns for the two £ow rates were signi¢cant. A




The results of the radiolabelling validation data are
shown inTable1.Themean FPFs for drug before labelling,
drug after labelling and radiolabel were 46.7, 49.3 and
39.9% of the delivered dose. Although the lower FPF for
radiolabel suggested that lung deposition might be
slightly underestimated in an in vivo scintigraphic study,
the radiolabelling method was considered suitable for
use. The radiolabel FPFs for the inhalers used on the
two study days on which subjects were dosed were 41.9
and 41.2 (mean 41.6%,Table1).
Delivereddose data
In vitro tests showed that themean (SD) delivered dose of
salbutamol per shot was101.7 (9.0) and 98.3 (8.1)mg for 2
inhalers at 60 l/min, and 98.1 (9.3) and101.9 (7.4)mg salbu-
tamol for 2 inhalers at 30 l/min (Table 2).The actual deliv-
ered dose from two shots was therefore assumed to be
identical to the nominal value of 200mg at both £ow
rates.
In vivo data
The fractionation of the delivered dose between lungs,
oropharynx and exhaled air is shown in Table 3. There
was a small but signi¢cant di¡erence betweenmean (SD)
% lung depositions at fast [26.4 (4.3)%] and slow [21.1
(5.1)%] PIFRs (Po0.05). These ¢gures corresponded to
52.8 (8.6) and 42.2 (10.2)mg salbutamol deposited in the
lungs at fast and slow PIFRs, respectively (Po0.05), as-
TABLE 1. Mean (SD) percentage distributionsofdrugbeforelabelling, drugafterlabelling, andradiolabelwithin ahigh-precision









Inductionport (%) 31.8 (5.1) 24.6 (2.5) 30.3 (2.6) 26.4 (8.2)
Stage1 (%) 15.6 (1.4) 20.1 (1.5) 23.4 (1.7) 25.0 (6.0)
Stage 2 (%) 5.9 (1.2) 6.1 (1.0) 6.5 (0.9) 7.1 (2.6)
Stage 3 (%) 10.8 (1.2) 11.4 (0.8) 10.3 (0.6) 10.1 (1.3)
Stage 4 (%) 13.3 (1.1) 13.6 (1.1) 10.8 (0.8) 10.4 (0.5)
Stage 5 (%) 22.6 (1.2) 24.4 (1.0) 18.8 (0.5) 21.2 (1.3)
FPF (%)a 46.7 (3.3) 49.3 (1.2) 39.9 (1.3) 41.6 (0.5)
aSumof stages 3^5, expressed as % delivered dose.









93.2 91.8 87.2 92.0
88.0 96.2 83.9 92.0
102.5 102.2 102.9 96.5
96.7 104.1 88.8 104.8
96.0 107.6 95.5 103.9
107.6 96.7 101.7 110.8
97.5 104.1 96.5 113.7
106.1 93.0 111.7 106.2
116.3 105.9 107.4 101.4
113.1 81.2 105.7 97.6
Mean 101.7 98.3 98.1 101.9
SD 9.0 8.1 9.3 7.4
Grandmean (mg) 100.0 100.0
TABLE 3. Percentage of delivered dose deposited in the lungs and oropharynx, and on the exhaled air ¢lter at fast and slow
inhaled £owrates.The percentage ofthe dose deposited inperipheral, intermediate and centrallung zones, and the peripheral







Lungs (%) 26.4 (4.3) 21.1 (5.1) o0.05
Oropharynx (%) 72.5 (5.2) 78.7 (5.0) o0.05
Exhaled air (%) 1.2 (0.7) 0.2 (0.1) o0.01
Regionallungdeposition
Peripheral (P) zone (%) 10.0 (2.2) 8.3 (2.3) NS
Intermediate zone (%) 9.2 (1.4) 7.2 (1.9) o0.05
Central (C) zone (%) 7.2 (1.5) 5.6 (1.7) o0.05




























FIG. 2. Individual lung deposition values, expressed asmass of
salbutamol (mg) deposited in the lungs with maximal and sub-
maximal inspiratory e¡orts (peak inhaled £ow rates 60 and
30 l/min, respectively).
1030 RESPIRATORYMEDICINEsuming a total delivered dose of 200mg over 2 shots. In-
dividual values for the mass of salbutamol deposited in
the lungs are shown in Fig. 2, and were higher in 9 of 10
subjects with fast inhalation. Oropharyngeal deposition
was signi¢cantly higher at slow [78.7 (5.0)%] than at fast
[72.5 (5.2)%] PIFR (Po0.05), although the numerical dif-
ference between oropharyngeal depositions at the two
£ow rates was small. The exhaled fraction was signi¢-
cantly higher at the fast £ow rate, but averaged only1.2
and 0.2% of the dose at fast and slow PIFRs, respectively.
Regional lung deposition patterns are also shown inTable
3.Deposition in central and intermediate lung zones was
signi¢cantly (Po0.05) higher at the fast £ow rate, but
there was only a trend towards higher peripheral lung
zone deposition with fast inhalation. The P/C ratio did
not vary signi¢cantly between fast [1.4 (0.3)] and slow
[1.5 (0.6)] inhalations.
Inhaled£owrateswere close to targetedvalues [mean
PIFR 62.1l/min (range 46.0 ^ 73.0 l/min) and 36.3 l/min
(range 29.0 to 42.0 l/min)].The corresponding inhaled vo-
lumes were 3.1l (range 1.6 to 4.1l) and 3.3 l (range 2.1 l ^
4.5 l).
Therewere no signi¢cant changes in any lung function
parameter following inhalation of the radiolabelled for-
mulation. FEV1 averaged 3.89 (0.62) l before dosing, and
3.95 (0.65) l after dosing, at the fast £ow rate.The corre-
sponding values at the slow £ow rate were 3.86 (0.65) l
and 3.87 (0.69) l before and after dosing.
DISCUSSION
For many years, pMDIs have been the most widely used
type of asthma inhaler. Until very recently, pMDIs have
used CFC propellants to form the spray, but CFCs have
been implicated in causing damage to the ozone layer,
leading to a ban on their production throughout most
of the world (1). While some companies have reformu-lated their pMDIswith alternative ozone-friendlypropel-
lants (13,14), others have developed alternative delivery
systems. These have included DPIs, in which metered
amounts of drug powder are dispersed into the inhaled
airstream, usually by the patient’s own inspiratory e¡ort
(2,15).One of the additional bene¢ts of these ‘‘breath-ac-
tuated’’devices is that the patient does not have to coor-
dinate ¢ring the device with inhalation, a problem
associated with sub-optimal drug delivery using pMDIs.
However, a relateddisadvantage ofbreath-actuatedDPIs
is thatdrugdeliveryin vivo canbe a¡ectedby thepatient’s
PIFR, and hence upon the degree of inspiratory e¡ort
that each patient is willing or able to expend.
Traditional DPIs contain either discrete blisters or
capsules of powder, or dispense doses as freely £owing
powder from a reservoir (15).The MAGhaler device dif-
fers in that thepowder is containedwithin the device in a
highly compacted ring-shaped tablet, formed by a radial
isostatic compression process. The dose is metered by
the action of a blade, which mills an exact quantity of
powder from the compacted block, prior to inhalation
by the patient.This type of system has potential advan-
tages in terms of highly reproducible dosing, and protec-
tion of the powder from the e¡ects of environmental
moistureuntil the dosehasbeen cut from thering-tablet
(Mundipharma, data on ¢le). Isostatic compression en-
sures that there is no compression gradient through the
tablet, hence improving dose reproducibility throughout
the life of the inhaler.Density variationswithin the tablet
are less than 0.01%, enablinghighlyreproducible dosing to
be achieved (GGUGmbH, data on ¢le).
One of the key issues in gamma scintigraphic studies is
the validation of the radiolabellingmethod, in which it is
required to show that the drug and radiolabel are dis-
tributed in the same manner through di¡erent particle
size bands. This permits the radioactive counts to be
used to quantify where drug has been deposited. The
FPF of drug before the labelling process was 46.7% of
the emitted dose, and the FPFs of the radiolabel on the
two study days averaged 41.6%. Although these data
were onlyobtained in a small number of replicate experi-
ments, they represented a smallmismatchbetween drug
and radiolabel, and suggested that the lung deposition in
vivo may have been slightly underestimated. A ‘‘cor-
rected’’ value of lung depositionmaybe obtainedbymul-
tiplying the measured whole lung depositions by the
factor 46.7/41.6, i.e. 1.12. This calculation results in cor-
rected mean whole lung deposition values of 29.6 and
23.7% of the delivered dose at PIFRs of 60 and 30 l/min,
respectively. The coe⁄cient of variation of lung deposi-
tion (C of V, standard deviation expressed as a percen-
tage of themean) was16% at a PIFR of 60 l/min.
When the PIFRwas reduced from 60 to 30 l/min, lung
deposition fell from a mean 26.4% to a mean 21.1% of the
delivered dose. Although statistically signi¢cant, this fall
in lung deposition was numerically small, and probably
TABLE 4. Whole lungdeposition (% delivereddose) andinter-subjectcoe⁄cients of variationofwhole lungdeposition (Cof V,
%) for a range of drypowder inhalers assessed bygamma scintigraphy
Device Lungdeposition (%)a Cof V (%) Deposition at sub-maximalvs.
maximal £owrate
Reference
MAGhaler (Mundipharma) 26.4 16.3 0.80 Present study
Taifun (Leiras) 41.5 16.9 0.86 16
Turbuhaler (AstraZeneca) 32.0 34.3 0.53 17
Novolizer (ASTAMedica) 35.7 NA 0.62 18
Ultrahaler (Aventis) 13.6 36.1 0.74 8
Pulvinal (Chiesi) 14.8 22.7 0.83 19
Spinhaler (Aventis) 18.5 NA 0.42 20
aWithmaximal inspiratorye¡ort.
NA: data not available.
LUNGDEPOSITIONOFSALBUTAMOL 1031not clinically signi¢cant. As the delivered dose from the
device was essentially independent of inhaled £ow rate,
the di¡erence in lung depositions between the two in-
haled £ow rates remained small when the data were ex-
pressed as mass of salbutamol deposited in the lungs
(52.8mg vs. 42.2mg). In breath-actuated DPIs, lung de-
position generally falls with decreasing peak inhaled £ow
rate, as the shear forces needed either to de-aggregate
drug particles, or to separate drug from larger lactose
carrier particles, are reduced. However, the e¡ect of
£ow rate may be minimised in the MAGhaler, as the ac-
tuation process is intended to result in dose micronisa-
tion in situ.
In order to put the MAGhaler data into context, we
have compared themwith a range of other DPIs inTable
4, in terms of the following parameters: (a) whole lung
deposition as % delivered dosewithmaximal inspiratory
e¡ort (b) C of Vof lung depositionwithmaximal inspira-
tory e¡ort, and (c) the ratio of lung deposition with ap-
proximately half maximal inspiratory e¡ort to that with
maximal inspiratory e¡ort.These data were taken from
studies carried out in our unit with other breath-actu-
ated DPIs.Table 3 shows that the MAGhaler was among
themore e⁄cientdevices in terms of thenumerical value
of lung deposition. Additionally, lung deposition was
highly reproducible, andrelatively inhaled £owrate inde-
pendent. It is probable that this good performance re-
£ects properties of both device and formulation.Of the
devices compared, Taifun (16), Turbuhaler (17), Novolizer
(18) and Pulvinal (19) contain freely £owing powder for-
mulations dispensed from reservoirs, while Spinhaler
(20) contains the drug powder in gelatine capsules. The
formulation used in the Ultrahaler (8) has some similari-
ties to that in the MAGhaler, as the powder is com-
pressed into a ring-shaped block, from which doses are
metered. Drug deposition data that varies little with in-
spiratory e¡ort has also been reported previously for
other breath-actuated DPIs (16,21), and for a DPI where
the powder is dispersed by an internal electric motor
(22).However,when the e¡ectof inspiratorye¡ort upondrug delivery is very marked, therapeutic response may
be reduced (23).
The relative £ow independence of the MAGhaler
shouldbe especiallyuseful in groups of patientswhohave
di⁄culty inhaling maximally, which could include young
children, the elderly, and patients with severe respira-
tory impairment (15). By producing relatively high, rela-
tively reproducible and relatively inhalation £ow-
independent drug delivery to the lung, the MAGhaler
should be a valuable addition to the range of DPI devices
available for inhalation therapy, not just for salbutamol,
but for a much wider range of drugs that can be formu-
lated as dry powders.
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